Kalocyte, Inc.

Kalocyte, Inc. , based in the US, specializes in creating innovative solutions for blood loss management, particularly through its bio-inspired artificial red blood cell technology, ErythroMer. Kalocyte, Inc. is focused on developing advanced medical technologies to address blood loss challenges.

Founded in 2016 and headquartered in Baltimore, US, the company has undergone strategic pivots to enhance its product offerings. The founders, Dipanjan Pan and Phil Spinella, alongside CEO Elaine Haynes, have aimed to establish a strong presence in the medical sector. As of July 2023, Kalocyte secured USD 500,000 in venture funding from Maryland Technology Development Corporation, which forms part of their total amount raised of USD 500,000 from three deals. KaloCyte specializes in the development of ErythroMer, an innovative dried, bio-inspired artificial red blood cell designed to address critical challenges associated with blood loss, particularly in scenarios where stored red blood cells are either unavailable, undesirable, or in short supply.

ErythroMer acts as a substitute for traditional blood transfusions, using a first-in-class nano-encapsulated human hemoglobin that mimics the physiological functions of natural red blood cells. This product is particularly targeted towards emergency medical services, military applications, and regions facing healthcare resource constraints, such as underdeveloped countries. The company aims to serve healthcare providers, trauma care units, and organizations involved in pre-hospital and battlefield medical care. KaloCyte's innovations are positioned to have a global impact, with potential deployment in various geographical markets, including North America, Europe, and regions with high trauma rates or military presence.

KaloCyte has secured over USD 20 mn in federal grants and investor funding to support the development and commercialization of ErythroMer, positioning itself for future revenue generation through partnerships with government agencies and healthcare providers. The company engages in B2B transactions, collaborating with hospitals, trauma centers, and military organizations that require reliable blood substitutes for emergency care. The transaction structure involves direct sales and potential licensing agreements, where clients procure ErythroMer for use in critical care settings. The company is on track for first-in-human trials, which may lead to a structured rollout of ErythroMer in medical markets, establishing pricing frameworks based on partnership agreements and contractual obligations with healthcare institutions.

The focus on ErythroMer, as a flagship product, highlights KaloCyte's commitment to addressing life-threatening blood loss through innovative solutions. In July 2023, Kalocyte, Inc. raised USD 500,000 in venture funding from Maryland Technology Development Corporation. The funding will be utilized to support ongoing research and development initiatives.

The company is focused on preparing for the launch of ErythroMer, with plans to expand into international markets that face significant challenges with blood supply, including parts of Europe and regions with high military activity by 2024.